

# ONCODAILY MEDICAL JOURNAL

*abstract*

## **Hippocampus Sparing for Patients Undergoing Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma in Morocco: A Dosimetric Study**

**Mohammed Afif, Fadila Kouhen,  
Hanae Dlaimi**

DOI: 10.69690/ODMJ-018-3101-7089

**AMSTRO**

Asia and Middle East Society of  
Therapeutic Radiation and Oncology

Affiliated with ASTF

Asia and Middle East Society for Radiation Therapy and Oncology, 2026

*abstract*

## **Hippocampus Sparing for Patients Undergoing Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma in Morocco: A Dosimetric Study**

**Author:** Mohammed Afif<sup>1</sup>, Fadila Kouhen<sup>2</sup>,  
Hanae Dlaimi<sup>1</sup>

**Affiliation:** <sup>1</sup> Department of Radiotherapy, CHU  
Mohammed 6, Tangier, Morocco

<sup>2</sup> Department of Radiotherapy, Mohamed 6  
Hospital, UM6SS, Rabat, Morocco

**DOI:** 10.69690/ODMJ-018-3101-7089

**Introduction:** Our study aims to evaluate the dose received by the hippocampus for patients with undifferentiated carcinoma of the nasopharynx (UCNT) treated with volume-modulated arc therapy (VMAT).

**Methodology:** This retrospective study analyzed the dosimetric data of 20 patients with undifferentiated nasopharyngeal carcinomas treated with arc therapy (VMAT) for a total dose of 70 Gy delivered in 2 Gy daily fractions. Each case was compared with 2 dosimetric plans, a standard arcTherapy plan and an arc therapy plan with hippocampus sparing (HS-arc therapy). Hippocampus delineation was based on the RTOG contouring guidelines. Both hippocampi were delineated on axial imaging CT-scan, and MRI imaging fusion. The evaluation parameters include DMin, Dmean, and D40% doses received by the hippocampus, and the coverage of the target volume (PTV) evaluated by the V95% and the homogeneity index in both groups.

**Results:** The mean hippocampus volume was 6.24 cm<sup>3</sup> ( $\pm 2.61$  cm<sup>3</sup>), we had a reduction in the radiation doses received by the hippocampus, in particular the D40%, from 12.15 Gy ( $\pm 2.1$  Gy) in the ArcTherapy standard planes to 6.92 ( $\pm 1.5$  Gy) in the arcTherapy-HS planes ( $p$ -value  $< 0.001$ ), a decrease in the Dmoy from 10.73 ( $\pm 1.8$  Gy) to 7.40 Gy ( $\pm 1.3$  Gy) ( $p$ -value  $< 0.01$ ), and Dmin 5.87Gy ( $\pm 1.1$  Gy) Vs 3.93 Gy ( $\pm 0.9$  Gy) ( $p$ -value 0.05). The coverage of the target volume (PTV) was similar in both treatment plans.

**Conclusion:** Our dosimetric analysis suggests that, for patients undergoing VMAT radiotherapy for UCNT, hippocampus sparing significantly reduces the doses received by the hippocampus while ensuring good coverage of target volumes. However, the impact of hippocampus sparing on patients' quality of life requires more clinical studies focused on the cognitive functions of patients with UCNT.

**Conflict of interests:** The authors declare no conflict of interests.

**Funding:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**License:** © The Author(s) 2026. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, and unrestricted adaptation and reuse, including for commercial purposes, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>.